Showing results (1021-1030 of 6,768) with videos related to
Sort By:
Pageof 677
Clinical Therapeutics|February 23, 2010
Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose studySeong Bok Jang, Yoon Jung Lee, Lay Ahyoung Lim, et al.Clinical Therapeutics|January 30, 2010
Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasiaSara Schilit, Kenza E BenzeroualClinical Therapeutics|January 30, 2010
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with goutMichael E Ernst, Michelle A FravelClinical Therapeutics|January 30, 2010
Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthmaChristopher M Blanchette, Steven D Culler, Daniel Ershoff, et al.Clinical Therapeutics|January 30, 2010
In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US HospitalsKathryn J Eagye, Joseph L Kuti, Christina A Sutherland, et al.Clinical Therapeutics|January 30, 2010
The value of dividends in health: a call to align stakeholdersCyndy NayerClinical Therapeutics|January 30, 2010
Relative bioavailability of generic and branded 250-mg and 500-mg oral chlorphenesin carbamate tablets in healthy Korean volunteers: a single-dose, randomized-sequence, open-label, two-period crossover trialJi-young Yu, Hyun Ho Song, Bo Gyeom Kim, et al.Clinical Therapeutics|January 30, 2010
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterolChristian Frois, Eric Q Wu, Saurabh Ray, et al.Clinical Therapeutics|January 30, 2010
Dose accuracy and durability of the NovoPen 4 insulin delivery device before and after simulation of 5 years of use and under various stress conditionsCarsten M Kristensen, Morten DonsmarkClinical Therapeutics|January 30, 2010
Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertensionJuan G Puig, Heribert Schunkert, Addison A Taylor, et al.Pageof 677